Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Radiodermatitis × Radiotherapy × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 34 Carcinoma, Non-Small-Cell Lung 21 Head and Neck Neoplasms 18 Brain Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Glioma 9 Lung Neoplasms 8 Breast Neoplasms 8 Rectal Neoplasms 7 Carcinoma, Squamous Cell 7 Astrocytoma 7 Prostatic Neoplasms 6 Neoplasms 6 Mucositis 4 Carcinoma 4 Neoplasm Metastasis 3 Esophageal Squamous Cell Carcinoma 3 Esophageal Neoplasms 3 Colorectal Neoplasms 3 Xerostomia 2 Stomatitis 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Lymphoma 2 Leukemia 2 Laryngeal Diseases 2 Gliosarcoma 2 Adenocarcinoma Of Esophagus 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1

Interventions

Norepinephrine 3 Petrolatum 2 dimethicone 1 Standard of Care 1 Radiotherapy, Conformal 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07192588 2025-09-25

GuARD

Graegis Pharmaceuticals Ltd

Phase 2 Active not recruiting

Breast Neoplasms, Radiodermatitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡